PT  - JOURNAL ARTICLE
AU  - Miyakawa, Kei
AU  - Jeremiah, Sundararaj Stanleyraj
AU  - Ohtake, Norihisa
AU  - Matsunaga, Satoko
AU  - Yamaoka, Yutaro
AU  - Nishi, Mayuko
AU  - Morita, Takeshi
AU  - Saji, Ryo
AU  - Nishii, Mototsugu
AU  - Kimura, Hirokazu
AU  - Hasegawa, Hideki
AU  - Takeuchi, Ichiro
AU  - Ryo, Akihide
TI  - Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles
AID  - 10.1101/2020.07.20.20158410
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.20.20158410
4099  - http://medrxiv.org/content/early/2020/07/22/2020.07.20.20158410.short
4100  - http://medrxiv.org/content/early/2020/07/22/2020.07.20.20158410.full
AB  - SARS-CoV-2 neutralizing antibodies confer protective immunity against reinfection. We have developed a rapid test for screening SARS-CoV-2 neutralization antibodies using genome-free virus-like particles incorporated with a small luciferase peptide, HiBiT. Their entry into LgBiT-expressing target cells reconstitutes NanoLuc luciferase readily detected by a luminometer. This newly developed HiBiT-tagged Virus-like particle-based Neutralization Test (hiVNT) can readily quantify SARS-CoV-2 neutralizing antibodies within three hours with a high-throughput in a low biosafety setting. Moreover, the neutralizing activity obtained from hiVNT was highly consistent with that measured by the conventional neutralization test using authentic SARS-CoV-2. Furthermore, antibody responses to both viral spike and nucleocapsid proteins correlated with the neutralization activity assessed by hiVNT. Our newly-developed hiVNT could be instrumental to survey individuals for the presence of functional neutralizing antibody against SARS-CoV-2.Competing Interest StatementThe authors have no conflicts of interest directly relevant to the content of this article. YY is a current employee of Kanto Chemical Co. Inc.Funding StatementThis study was supported by Rapid research and development Projects on COVID-19 of AMED (JP19fk0108110), and Life Innovation Platform Yokohama from Economic Affairs Bureau City of Yokohama to AR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yokohama City University Certified Institutional Review Board (Reference No. B200200048, B160800009), and the protocols used in the study were approved by the ethics committee. Written informed consent was obtained from the patient or family/guardian.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available from the authors on request.